1242.6000 -0.60 (-0.05%)
NSE May 28, 2025 15:31 PM
Volume: 767.0K
 

1242.60
-0.05%
Axis Direct
The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio, vaccines, CDMO, and digital healthcare platforms. However, high inflation could decrease margins prompting us to reduce TP to Rs 4,500/share.
Number of FII/FPI investors decreased from 927 to 911 in Mar 2025 qtr
More from Dr. Reddy's Laboratories Ltd.
Recommended